Addition of Cetuximab Beneficial in Metastatic Colorectal Cancer
the Cancer Therapy Advisor take:
According to a new study published in the Journal of Clinical Oncology, researchers have found that patients metastatic RAS wild-type colorectal cancer derived a significant benefit from the addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment, while those with RAS tumors did not.
The phase III CRYSTAL study found that the addition of cetuximab to FOLFIRI significantly improved objective response, progression-free survival, and overall survival in the first-line treatment of patients with KRAS codon 12/13 (exon 2) wild-type metastatic colorectal cancer, but researchers sought to perform subgroup analyses to determine if those with RAS wild-type tumors particularly benefit from the addition of immunotherapy.
Researchers detected other RAS mutations in 14.7% of 430 evaluable patients with KRAS exon 2 wild-type tumors. They found that those with RAS wild-type tumors had significantly improved overall survival, progression-free survival, and objective response from the addition of cetuximab to FOLFIRI.
However, patients with other RAS tumor mutations did not improved efficacy outcomes. The findings suggest that patients with KRAS exon 2 wild-type tumors should be tested for all activating RAS mutations before healthcare providers consider cetuximab therapy in order to identify those patients that will benefit the most.
Patients metastatic RAS wild-type colorectal cancer derived a significant benefit from the addition of cetuximab.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer